Lipodystrophy

1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
1 program
1
Sculptra InjectionPhase 41 trial
Active Trials
NCT00360139Withdrawn15Est. Dec 2008
Regeneron
RegeneronTARRYTOWN, NY
1 program
REGN4461N/A1 trial
Active Trials
NCT04710056Available
Bristol Myers Squibb
1 program
metreleptinN/A1 trial
Active Trials
NCT00677313Completed41Est. Jan 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SanofiSculptra Injection
Bristol Myers Squibbmetreleptin

Clinical Trials (3)

Total enrollment: 56 patients across 3 trials

NCT00360139SanofiSculptra Injection

Clinical Trial to Determine the Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy

Est. completion: Dec 200815 patients
Phase 4Withdrawn

Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling

N/AAvailable

An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy

Start: Mar 2009Est. completion: Jan 201541 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space